For: | Gadde S, Lee B, Kidd L, Zhang R. Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy. World J Nephrol 2016; 5(6): 547-550 [PMID: 27872837 DOI: 10.5527/wjn.v5.i6.547] |
---|---|
URL: | https://www.wjgnet.com/2220-6124/full/v5/i6/547.htm |
Number | Citing Articles |
1 |
Mingshu Li, Jun Chen, Zhixiong Fang, Yi Li, Qian Lin. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virology Journal 2019; 16(1) doi: 10.1186/s12985-019-1140-x
|
2 |
Samuel Deshayes, Charles Dolladille, Anaël Dumont, Nicolas Martin Silva, Basile Chretien, Hubert De Boysson, Joachim Alexandre, Achille Aouba. A Worldwide Pharmacoepidemiologic Update on Drug‐Induced Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the Era of Targeted Therapies. Arthritis & Rheumatology 2022; 74(1): 134 doi: 10.1002/art.41902
|
3 |
Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir. Canadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/1632959
|
4 |
Lawrence Hyun Kwon, Jennifer Griffiths, Lanny DiFranza. Acute kidney injury and ANCA positivity in a patient treated with glecaprevir/pibrentasvir: a case report. Frontiers in Medicine 2025; 11 doi: 10.3389/fmed.2024.1434497
|
5 |
Youssef K. Ahmad, Salwa Tawfeek, Mohamed Sharaf-Eldin, Hassan E. Elbatea, Abdelrahman Kobtan, Ferial El-Kalla, Rehab Badawi, Sherief Abd-Elsalam. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hospital Pharmacy 2017; 52(4): 294 doi: 10.1310/hpx5204-294
|
6 |
Yosra Zaimi, Myriam Ayari, Nadine Ghithia, Shema Ayadi. Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir
Treatment: A Case Report. Current Drug Safety 2024; 19(1): 145 doi: 10.2174/1574886318666230406083939
|
7 |
Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes. Possible acute rejection associated with the use of the new antihepatitis C virus medications. Avicenna Journal of Medicine 2019; 9(01): 32 doi: 10.4103/AJM.AJM_171_17
|
8 |
Elena Campione, Annunziata Dattola, Monia Di Prete, Daniele Di Paolo, Amedeo Ferlosio, Augusto Orlandi, Luca Bianchi. Sofosbuvir induced leucocytoclasic vasculitis: a case report. BMC Dermatology 2019; 19(1) doi: 10.1186/s12895-019-0086-4
|
9 |
Youssef K. Ahmad, Salwa Tawfeek, Mohamed Sharaf-Eldin, Hassan E. Elbatea, Abdelrahman Kobtan, Ferial El-Kalla, Rehab Badawi, Sherief Abd-Elsalam. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hospital Pharmacy 2017; 52(4): 294 doi: 10.1310/hpx5204-294
|
10 |
Hany E. Elmekkawy, Mohamed S. Emam, Magda S. Abdelaziz, Mai I. Mehrez, Yomna A. Alahmadawy. Role of optical coherence tomography angiography in detecting possible retinal vascular complications of sofosbuvir and daclatasvir in patients with hepatitis C virus infection. Delta Journal of Ophthalmology 2021; 22(2): 132 doi: 10.4103/DJO.DJO_70_20
|
11 |
Kinanah Yaseen, Alana Nevares, Hiromichi Tamaki. A Spotlight on Drug-Induced Vasculitis. Current Rheumatology Reports 2022; 24(11): 323 doi: 10.1007/s11926-022-01088-0
|